IP Library Granted Patent US 7,879,028
Granted Patent B2
US 7,879,028 · App. 12/658,570 · Granted Feb 1, 2011

Osmotic delivery systems and piston assemblies for use therein

Assignee: Intarcia Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,879,028
App. No.
12/658,570
Granted
Feb 1, 2011
Kind
B2
Abstract

An osmotic delivery system is disclosed for delivering an active agent formulation to a fluid environment. The osmotic delivery system typically comprises a reservoir having a lumen that contains the active agent formulation and an osmotic agent formulation and a piston assembly positioned in the lumen to isolate the active agent formulation from the osmotic agent formulation. The piston assembly typically comprises a body constructed and arranged for positioning in the lumen. The body is typically made of a polymeric material that is, for example, resistant to leaching in an organic solvent. In one embodiment, the body is a columnar body having a rim at a distal end thereof for engaging and sealing against a wall of the reservoir and the piston assembly further comprises a spring retained at the distal end of the columnar body for biasing the rim of the columnar body against the wall of the reservoir.

Claims (29)

1. A piston assembly for positioning in a lumen of a reservoir for an osmotic delivery system, comprising

a columnar body constructed and arranged for positioning in the lumen, wherein the columnar body has a core made of a polymeric material comprising an ultra high molecular weight polyethylene, the columnar body further comprising a rim at a distal end thereof for engaging and sealing against an interior wall of the reservoir and a spring retained at the distal end for biasing the rim against the interior wall of the reservoir.

2. The piston assembly of claim 1 , wherein the spring is a radial spring.

3. The piston assembly of claim 2 , wherein the spring is a canted coil spring.

4. The piston assembly of claim 1 , wherein the spring is made of a non-reactive metal.

5. The piston assembly of claim 1 , wherein the polymeric material produces volatile leachates of less than about 1.4 μg/ml when exposed to benzyl benzoate at 40° C. for at least about 45 days.

6. An osmotic delivery system for delivering an active agent formulation to a fluid environment, comprising:

a reservoir, comprising an interior wall, that defines a lumen containing the active agent formulation and an osmotic agent formulation; and

the piston assembly of claim 1 positioned in the lumen to isolate the active agent formulation from the osmotic agent formulation, wherein the piston assembly engages and seals against the interior wall of the reservoir.

7. The osmotic delivery system of claim 6 , further comprising a semipermeable membrane positioned at a first end of the reservoir adjacent the osmotic agent formulation.

8. The osmotic delivery system of claim 7 , further comprising a flow modulator positioned at a second end of the reservoir adjacent the active agent formulation, said flow modulator having an orifice for delivering the active agent formulation to the fluid environment.

9. The osmotic delivery system of claim 6 , wherein the active agent formulation is a suspension formulation comprising a suspension vehicle comprising one or more organic solvent.

10. The osmotic delivery system of claim 9 , wherein the suspension formulation further comprises a particle formulation comprising one or more polypeptide selected from the group consisting of interferons and insulinotropic peptides.

11. The osmotic delivery system of claim 10 , wherein the polypeptide is selected from the group consisting of alpha interferon, beta interferon, delta interferon, gamma interferon, omega interferon, lambda interferon, tau interferon, interferon analog polypeptides, interferon derivative polypeptides, and mixtures thereof.

12. The osmotic delivery system of claim 10 , wherein the polypeptide is selected from the group consisting of glucagon like protein 1 (GLP-1), GLP-1 derivative polypeptides and analog polypeptides, exendin-4, and exendin-4 derivative polypeptides and analog polypeptides.

13. A method of manufacturing the osmotic delivery system of claim 6 , comprising

providing the reservoir, the active agent formulation, the osmotic agent formulation, the piston assembly, a semipermeable membrane and a flow modulator;

assembling the reservoir, the active agent formulation, the osmotic agent formulation, the piston assembly, the semipermeable membrane and the flow modulator, such that the piston assembly is positioned in the lumen to isolate the active agent formulation from the osmotic agent formulation, the semipermeable membrane is positioned at a first end of the reservoir adjacent the osmotic agent formulation, and the flow modulator is positioned at a second end of the reservoir adjacent the active agent formulation.

14. An osmotic delivery system for delivering an active agent formulation to a fluid environment, comprising:

a reservoir, comprising an interior wall, that defines a lumen containing the active agent formulation and an osmotic agent formulation;

the active agent formulation comprising

a suspension vehicle, the suspension vehicle comprising benzyl benzoate and polyvinylpyrrolidone, and

a particle formulation comprising an insulinotropic polypeptide;

a piston assembly positioned in the lumen of the reservoir, the piston assembly comprising

a columnar body having a core made of a polymeric material comprising an ultra high molecular weight polyethylene, the columnar body further comprising a rim at a distal end thereof for engaging and sealing against the interior wall of the reservoir and a spring retained at the distal end for biasing the rim against the interior wall of the reservoir, wherein the piston assembly isolates the active agent formulation from the osmotic agent formulation;

a semipermeable membrane positioned at a first end of the reservoir adjacent the osmotic agent formulation; and

a flow modulator positioned at a second end of the reservoir adjacent the active agent formulation, said flow modulator having an orifice for delivering the active agent formulation to the fluid environment.

15. The osmotic delivery device of claim 6 , wherein the insulinotropic polypeptide is selected from the group consisting of glucagon like protein 1 (GLP-1), GLP-1 derivative polypeptides and analog polypeptides, exendin-4, and exendin-4 derivative polypeptides and analog polypeptides.

16. The osmotic delivery system of claim 15 , wherein the insulinotropic polypeptide is exendin-4.

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Apr 17, 2020
From: MIDCAP FINANCIAL TRUST, AS AGENT
To: INTARCIA THERAPEUTICS, INC.; INTARCIA IRELAND LIMITED
Reel/Frame 052433/0001 →
RELEASE OF SECURITY INTEREST Recorded Jan 29, 2020
From: BAUPOST PRIVATE INVESTMENTS BVIV-3, L.L.C. AS COLLATERAL AGENT
To: INTARCIA THERAPEUTICS, INC.
Reel/Frame 051739/0453 →
SECURITY INTEREST Recorded Oct 23, 2019
From: INTARCIA THERAPEUTICS, INC.
To: BAUPOST PRIVATE INVESTMENTS BVIV-3, L.L.C., AS COLLATERAL AGENT
Reel/Frame 050801/0267 →
SECURITY INTEREST Recorded Oct 9, 2019
From: INTARCIA THERAPEUTICS, INC.; INTARCIA IRELAND LIMITED
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 050673/0020 →
RELEASE OF SECURITY INTEREST Recorded Oct 23, 2015
From: U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: INTARCIA THERAPEUTICS, INC.
Reel/Frame 036942/0544 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 16, 2015
From: ALESSI, THOMAS R.; DESJARDIN, MICHAEL A.; LAM, STAN; LAUTENBACH, SCOTT D.; ZAMORA, PAULINE C.
To: INTARCIA THERAPEUTICS, INC.
Reel/Frame 034740/0139 →
SECURITY AGREEMENT Recorded Nov 14, 2012
From: INTARCIA THERAPEUTICS, INC.
To: U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 029299/0678 →
RELEASE OF SECURITY INTEREST Recorded Sep 23, 2011
From: OXFORD FINANCE CORPORATION; SILICON VALLEY BANK
To: INTARCIA THERAPEUTICS, INC.
Reel/Frame 026962/0062 →
SECURITY AGREEMENT Recorded Sep 8, 2010
From: INTARCIA THERAPEUTICS, INC.
To: OXFORD FINANCE CORPORATION; SILICON VALLEY BANK
Reel/Frame 024953/0525 →
Continuity (4)
Continuation 1189083600 · Aug 8, 2007
Provisional Application 6082183000 · Aug 9, 2006
Provisional Application 6093020500 · May 15, 2007
Related Publication 20100185184A1 · Jul 22, 2010